4.5 Article

Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels

期刊

ORPHANET JOURNAL OF RARE DISEASES
卷 17, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13023-022-02465-9

关键词

Pantothenate kinase; Pantothenate kinase-associated neurodegeneration; Coenzyme A; Acyl carrier protein; Pantothenate; Pantethine; Vitamin E; Omega 3; Carnitine; Thiamine

资金

  1. Instituto de Salud Carlos III, Spain [FIS PI16/00786, PI19/00377]
  2. Fondo Europeo de Desarrollo Regional (FEDER-Union Europea), Proyectos de Investigacion de Excelencia de la Junta de Andalucia [CTS-5725, PY18-850]

向作者/读者索取更多资源

The study examined the therapeutic effectiveness of commercial supplements in mutant PANK2 cells, finding that these supplements were able to eliminate iron accumulation, increase expression levels of key enzymes, and improve pathological alterations.
Background Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurogenetic disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. Pantothenate kinase-associated neurodegeneration (PKAN) is one of the most widespread NBIA subtypes. It is caused by mutations in the gene of pantothenate kinase 2 (PANK2) that result in dysfunction in PANK2 enzyme activity, with consequent deficiency of coenzyme A (CoA) biosynthesis, as well as low levels of essential metabolic intermediates such as 4 '-phosphopantetheine, a necessary cofactor for essential cytosolic and mitochondrial proteins. Methods In this manuscript, we examined the therapeutic effectiveness of pantothenate, panthetine, antioxidants (vitamin E and omega 3) and mitochondrial function boosting supplements (L-carnitine and thiamine) in mutant PANK2 cells with residual expression levels. Results Commercial supplements, pantothenate, pantethine, vitamin E, omega 3, carnitine and thiamine were able to eliminate iron accumulation, increase PANK2, mtACP, and NFS1 expression levels and improve pathological alterations in mutant cells with residual PANK2 expression levels. Conclusion Our results suggest that several commercial compounds are indeed able to significantly correct the mutant phenotype in cellular models of PKAN. These compounds alone or in combinations are of common use in clinical practice and may be useful for the treatment of PKAN patients with residual enzyme expression levels.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据